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INTRODUCTION
Given the absence of available disease-modifying 
therapies for the treatment of Alzheimer’s disease 
(AD)  1, there is a great need in preventing and de-
laying the onset of cognitive impairment in healthy 
older subjects. In the last decade, many observation-
al studies have shown a wide variety of potentially 
modifiable risk factors for cognitive impairment, that 
have been proposed as targets for preventive strate-
gies 2. In addition to cardiovascular risk factors, psy-
chological conditions, education level, engagement 
In the last decade, the association between diet and cognitive function/dementia has been largely investi-
gated in observational studies, while there was a lack of evidence from randomized clinical trials (RCTs) on 
the prevention of late-life cognitive disorders though dietary intervention in cognitively healthy older adults. 
In the present article, we reviewed RCTs published in the last three years (2014-2016) exploring nutrition-
al intervention efficacy in preventing the onset of late-life cognitive disorders and dementia in cognitively 
healthy subjects aged over 60  years using different levels of investigation (i.e., dietary pattern changes/
medical food/nutraceutical supplementation/multidomain approach and dietary macro- and micronutrient 
approaches). From the included RCTs, there was moderate evidence that intervention through dietary pat-
tern changes, medical food/nutraceutical supplementation, and multidomain approach improved specific 
cognitive domains or cognitive-related blood biomarkers. Moreover, there was high evidence that protein 
supplementation improved specific cognitive domains. For fatty acid supplementation, mainly long-chain 
polyunsaturated fatty acids, there was emerging evidence suggesting an impact of this approach in im-
proving specific cognitive domains, MRI findings, and/or cognitive-related biomarkers also in selected sub-
groups of older subjects although some results were conflicting. Moreover, there was convincing evidence 
of an impact of non-flavonoid polyphenol and flavonoid supplementations in improving specific cognitive 
domains and/or MRI findings. Finally, there was only low evidence suggesting efficacy of intervention with 
homocysteine-related vitamins in improving cognitive functions, dementia incidence, or cognitive-related 
biomarkers in cognitively healthy older subjects.
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in social and mentally stimulating activities, sensory 
changes, lifestyle including diet, physical activity and 
voluptuary habits has obtained a crucial role  2  3. In 
particular, in the last years, a growing body of evi-
dence has been focused on the association between 
dietary habits and cognitive performance  3. Several 
nutritional supplements have been studied for their 
potential role as neuroprotective interventions use-
ful in delaying the onset of cognitive decline in older 
adults  4-7. Observational studies have showed that 
specific micro- or macronutrients such as polyun-
saturated fatty acids (PUFAs), vitamins, flavonoids 
are associated with a significantly reduced risk of 
dementia  3  8. This protective effect could be medi-
ated by several pathobiological pathways involved 
in AD development as amyloid-β (Aβ) deposition, 
neurofibrillary degeneration, synapse loss, inflam-
mation, oxidative stress, mitochondrial dysfunction, 
loss of vascular integrity and neuronal injury  8. Fur-
thermore, several evidences underlined that foods 
and nutrients properly combined into specific dietary 
patterns may act synergistically amplifying the health 
effects of single components  3 9-14. In particular, the 
Mediterranean dietary pattern has been the first and 
widely well studied and proposed in epidemiological 
studies, showing a strong protective role in cardio-
vascular and cognitive aging 3 9-11. Considering these 
promising results and the growing interest in this field, 
several randomized clinical trials (RCTs) investigated 
nutritional interventions as preventive or therapeutic 
approaches for cognitive function obtaining contrast-
ing results. Furthermore, in the last few years, the 
approach to the study of the relationship between 
diet and cognitive impairment has been changed. In 
fact, according to the National Institute on Aging-Alz-
heimer’s Association (NIA-AA) guidelines for AD 
and cognitive decline due to AD pathology 15, it has 
been suggested a direct impact of nutrition to brain 
structure and activity changes. This consideration in 
addition to the need to objectively quantify the effects 
of nutrients on cognitive outcomes not only in terms 
of neuropsychological test scores o clinical scales, 
has opened the era of brain imaging biomarkers in 
nutritional research. Another feature to underline was 
the emerging use of objective measures of dietary 
habits, not only in terms of daily questionnaires, but 
also biomarkers in order to achieve more reliable fin-
dings. The aim of the present article was to provide a 
comprehensive and updated review focusing on the 
RCTs published in the past 3 years (2014-2016) ex-
ploring nutritional interventions efficacy in preventing 
the onset of late-file cognitive disorders and demen-
tia in cognitively healthy subjects aged 60 years and 
older. 
NUTRITIONAL INTERVENTION THROUGH 
DIETARY PATTERN CHANGES, MEDICAL FOOD/
NUTRACEUTICAL SUPPLEMENTATION AND 
MULTIDOMAIN APPROACH
Dietary pattern changes
We used a narrative synthesis to summarize the find-
ings of the included studies, subdividing the articles 
for the three principal diet-based approaches (dietary 
patterns/medical food/nutraceutical supplementation/
multidomain approach, macronutrients, and micronu-
trients), specifying sample size and the cognitive out-
comes of the included studies (Tabs.  I-III)  16-43. Table  I 
shows selected RCTs published in the last three years 
(2014-2016) that evaluated the efficacy of nutritional 
intervention through dietary pattern changes, medical 
food/nutraceutical supplementation, and multidomain 
approach in preventing the onset of late-life cognitive 
disorders and dementia in cognitively healthy subjects 
aged over 60 years 16-23. The Mediterranean diet (MeDi), 
the typical dietary pattern of Mediterranean countries, 
has been the most studied dietary pattern, with a pro-
posed protective role against cognitive decline and 
dementia. The main components of the MeDi pattern 
are fruits, vegetables, legumes, cereals and olive oil 
as the main added lipid, associated with a moderate 
consumption of red wine and low consumption of red 
meat and dairy products. In particular, the findings 
from prospective observational studies and very re-
cent systematic reviews and meta-analyses of pooled 
studies suggested that higher adherence to the MeDi 
fulfilling the whole-diet approach was associated with a 
reduced risk of cognitive impairment, MCI and AD, as 
well as the transition from MCI to AD 3 9-11. Moreover, a 
recent systematic review on this issue suggested that 
also other emerging healthy dietary patterns such as the 
Dietary Approach to Stop Hypertension (DASH) and the 
Mediterranean-DASH diet Intervention for Neurodegen-
erative Delay (MIND) diets were associated with slower 
rates of cognitive decline and significant reduction of 
AD rate 3. Despite observational studies showed a posi-
tive significant association of certain healthy dietary pat-
terns with cognitive impairment, only few interventional 
studies have been conducted on dietary patterns, par-
ticularly on MeDi, reporting contrasting findings. In fact, 
in a RCT including 447 cognitively normal participants 
randomly assigned to a MeDi supplemented with extra-
virgin olive oil (EVOO) or with mixed nuts, or a control 
diet for a 4.1 years follow-up, those allocated to a MeDi 
plus EVOO scored better on the episodic memory and 
attention tasks compared with the control group. Fur-
thermore, compared with controls, this RCT showed a 
significant improvement in memory composite in the 
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MeDi plus nuts group and a significant improvement 
in frontal and global cognition composites in the MeDi 
plus EVOO group (Tab. I) 16. Furthermore, in a large RCT 
recruiting 48,835 women (50-79 years) for a follow-up 
of mean length of 8.1 years, dietary intervention based 
on caloric fat restriction and increasing consumption of 
vegetables, fruit and grain had no significant effects on 
cognition, with small significant improvements in three 
health-related quality of life subscales: general health, 
physical functioning, and vitality at one year follow-up 
(Tab. I) 17.
MeDical fooD/nutraceutical suppleMentation
In the last decade, several RCTs have proposed med-
ical foods/nutraceuticals as preventive or therapeutic 
approaches for cognitive decline and dementia, ac-
cording to the increasing knowledge about the potential 
beneficial effect of specific nutrients properly combined 
in selected dietary patterns.44 In the last three years, 
some medical foods/nutraceuticals have been tested 
in cognitively healthy subjects in order to delay cogni-
tive impairment obtaining good results only in specific 
cognitive domains (Tab. I) 18-21. In a RCT, 105 cognitively 
intact adults were randomized to receive a pill-based 
nutraceutical (NT-020), a proprietary formulation of blue-
berry, green tea extract (95% polyphenols), carnosine, 
blueberry extract (40% polyphenolics, 12.5% anthocy-
anins), and vitamin D3 (2000  IU per serving) and also 
contains grape polyphenolics, including 5% resveratrol 
or placebo using a battery of neuropsychological tests 
assessing six broad cognitive domains (episodic mem-
ory, processing speed, verbal ability, working memory, 
executive functioning, and complex speed) at baseline 
and eight weeks later. The NT-020 group exhibited bet-
ter performance on two measures of processing speed 
than the placebo group at eight weeks of follow-up 
(Tab.  I) 18. Among nutraceutical compounds and com-
binatorial formulations, Ginkgo biloba extract is prob-
ably the most widely studied and used herbal-based 
medication for the prevention and treatment of AD and 
late-life cognitive decline  45. Notwithstanding negative 
meta-analytic findings and the discouraging results 
of preventive trials against AD, some RCTs focusing 
particularly on dementia, AD, and MCI subgroups with 
neuropsychiatric symptoms and some recent me-
ta-analyses have suggested a renowned role for Ginkgo 
biloba extract for cognitive impairment and dementia 45. 
A RCT on 97 cognitively healthy older adults with no 
history of significant cognitive deficits reported modest 
effects of Ginkgo biloba plus choline-based formula on 
specific cognitive domains (executive functioning and 
verbal fluency) and immune functioning (Tab.  I)  19. An 
interesting RCT including 116 healthy cognitively older 
participants investigated the effects of supplementation 
with two multivitamin, mineral and herbal supplements, 
a women’s formula and a men’s formula in women 
and men, respectively. Assessments at baseline and 
post-supplementation included computerized cognitive 
tasks and blood biomarkers relevant to cognitive aging. 
After 16 weeks of follow-up, no cognitive improvements 
were observed after supplementation with either for-
mula, while several significant improvements were ob-
served in cognitive-related blood biomarkers including 
increased levels of vitamins B6 and B12 in women and 
men, reduced C-reactive protein in women, reduced 
homocysteine (Hcy) and marginally reduced oxidative 
stress in men, as well as improvements to the lipid pro-
file in men (Tab. I) 20. Finally, in one RCT, 27 postmeno-
pausal women received either a combination of 1 g do-
cosahexaenoic acid (DHA), 160 mg eicosapentaenoic 
acid (EPA), 240 mg Ginkgo biloba, 60 mg phosphati-
dylserine, 20 mg d-α tocopherol, 1 mg folic acid, and 
20 µg vitamin B12 per day or placebo for 6 months. The 
intervention resulted in significant effects in two of the 
four cognitive tests, with shorter mean latencies in a 
motor screening task, and more words remembered, 
and one of the three primary mobility measures with 
improved habitual walking speed. Compared with the 
placebo group, supplementation also resulted in signifi-
cantly higher blood DHA levels (Tab. I) 21.
MultiDoMain approach
Considering the great interest on the relationships 
between an healthy lifestyle including optimal dietary 
habits and physical activity and an healthy cognitive 
aging, some studies have proposed a multidomain 
approach as an effective preventive approach for cog-
nitive impairment or dementia (Tab. I) 22 23. The findings 
of several RCTs have suggested that some single-do-
main interventions, i.e., antihypertensives, nutritional 
supplements, cognitive training, and physical activity, 
had protective effects on cognitive decline 46, but these 
results have seldom been replicated in larger samples. 
In two 24-week RCTs carried out in parallel, 127 older 
subjects performed a resistance-type physical exercise 
program or not and, in both studies, subjects were 
randomly allocated to either a protein drink (2×15  g 
daily) or a placebo one. In frail and pre-frail older adults, 
resistance-type exercise training combined with protein 
supplementation significantly improved information 
processing speed, whereas exercise training alone 
had significant good effects on attention and working 
memory. There were no significant differences among 
the intervention groups on the other cognitive tests or 
domain scores (Tab. I) 22. Finally, in 2015, a successful 
2-year multi-domain lifestyle intervention was complet-
ed aiming at prevention of cognitive decline, the Finn-
ish Geriatric Intervention Study to Prevent Cognitive 
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Table I. Randomized clinical trials evaluating the efficacy of nutritional intervention through dietary pattern changes, medical food/
nutraceutical supplementation, and multidomain approach in preventing the onset of late-life cognitive disorders and dementia in 
cognitively healthy subjects aged over 60 years (2014-2016).
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and nutritional 
assessment
Principal results
Dietary pattern changes
Valls-Pedret et 
al., 2015 16
447 cognitively healthy 
older subjects
Mean age: 68.2 ± 6.3 years 
for the intervention group 
and 68.8 ± 6.5 years for the 
placebo group
MeDi + EVOO (1L/week)
MeDi + mixed nuts (30 g/
day)
Control diet (advice to 
reduce dietary fat)
4.1 years 
(median)
MMSE, AVLT, ASF,
DS-WAIS, VPA-WAIS,
CTT
In an older population, a MeDi 
supplemented
with EVOO or nuts was associated 
with improved episodic memory and 
frontal and global cognition 
Assaf et al., 
2016 17
48.835 older women
Aged: 50-79 years
Intervention group: reduced 
calories from fat to 20%, 
increased vegetables and 
fruit to 5+ servings, and 
increased grain servings to 
6+ servings a day Placebo
8.1 ± 1.7 
years
(max. 11.2 
yeas)
3MSE, RAND36
WHI FFQ.
No significant improvement in 
cognitive functions. Small significant 
improvements in three health-related 
quality of life subscales: general 
health, physical functioning, and 
vitality at 1 year follow-up
Medical food/nutraceutical supplementation
Small et al., 
2014 18
105 cognitively intact adults
Aged: 65-85 years
Nutraceutical NT-020
Placebo
8 weeks MMSE, AVLT, IPT, NC, TMT-A 
and –B, FBDS-WAIS, CF, 
COWAT, DST
Better performance for the NT-020 
group in two measures of processing 
speed (IPT and NC) compared to 
placebo group
Lewis et al., 
2014 19
97 cognitively healthy older 
subjects
MMSE ≥ 23
Aged ≥ 60 years
Nutraceutical formulation 
with:  Ginkgo biloba leaf 
(120 mg/day), Ginkgo 
biloba whole extract (80 
mg/day), grape seed 
extract (40 mg/day), Gotu 
kola leaf (Centella asiatica), 
dried buckwheat leaf juice, 
buckwheat seed, and 
soybean lecithin powder + 
Choline (700 mg/day)
Nutraceutical formulation 
with: grape seed extract 
(100 mg/day), green 
tea extract (50 mg/day, 
60% catechins),  bilberry 
fruit (50 mg/day, 25% 
anthocyanins), dried 
buckwheat leaf and juice, 
green tea leaf powder, 
and dried carrot root + 
nutraceutical formulation 
with: vitamin D (312 IU/
day), vitamin A (1,600 IU/
day), vitamin C (5.3 mg/
day), thiamine (0.3 mg/
day), riboflavin (0.3 mg/
day), vitamin B6 (1.3 mg/
day), defatted wheat germ, 
carrot (root), calcium 
lactate, nutritional yeast, 
bovine adrenal, bovine 
liver, magnesium citrate, 
bovine spleen, ovine 
spleen, bovine kidney, 
dried pea (vine) juice, 
dried alfalfa (whole plant) 
juice, mushroom, oat flour, 
soybean lecithin, and rice 
bran
Placebo
6 months MMSE, SCWT, TMT-A and -B, 
COWAT, DS-WAIS-III, HVLT-R
Immune function markers
Isolated and modest effects of a 
Ginkgo biloba plus choline-based 
formula on cognitive (executive 
functioning and verbal fluency) and 
immune functioning among healthy 
older adults with no history of 
significant cognitive deficits
u
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Impairment and Disability (FINGER) (Tab.  I)  23, with di-
etary counselling as one of the intervention domains (di-
et, exercise, cognitive training, vascular risk monitoring) 
and a control group (general health advice). Intervention 
goals were based on Finnish dietary recommendations. 
This 2-year multidomain lifestyle intervention was con-
ducted on 631 participants in the intervention and 629 
in the control group, aged 60-77 years at baseline with 
an estimated mean change in neuropsychological test 
battery total Z score at 2 years of 0.2 in the intervention 
group and 0.16 in the control group. These findings from 
the FINGER suggested that a multidomain intervention 
could improve or maintain cognitive functioning in at-
risk older people from the general population (Tab. I) 23. 
NUTRITIONAL INTERVENTION THROUGH 
MACRONUTRIENT CHANGES
Table  II shows selected RCTs published in the last 
three years (2014-2016) that evaluated the efficacy of 
nutritional intervention through supplementation of di-
etary macronutrients in preventing the onset of late-life 
cognitive disorders and dementia in cognitively healthy 
subjects aged over 60 years  24-34. In particular, many 
interventional RCTs evaluated the cognitive impact of 
macronutrient intakes such as proteins and PUFAs with 
promising results. 
proteins
Many RCTs evaluated protein intake as a supplemen-
tation in nondemented older adults showing significant 
improvement in specific cognitive domains (Tab. II) 24-27. 
Interestingly, these RCTs reported also promising results 
not only in terms of cognitive outcomes, but also mag-
netic resonance imaging (MRI) findings. In one RCT on 
65 frail or pre-frail cognitively healthy older subjects ran-
domly assigned to protein drink or placebo for 24 weeks, 
protein supplementation improved reaction time per-
formance, but did not improve the cognitive domains 
of episodic memory, attention and working memory, 
information processing speed, and executive functioning 
(Tab. II) 24. Promising results have been reported in a trial 
including 51 cognitively healthy older subjects [Mini-men-
tal State Examination (MMSE) > 15] randomly assigned 
to dietary carnosine and anserine (carnosine related 
compounds, CRC) supplementation (chicken meat ex-
tract) or placebo. In this trial, a significant improvement 
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and nutritional 
assessment
Principal results
Multidomain approach
Harris et al., 
2015 20
116 healthy older 
participants
Aged: 55-65 years
Multivitamin, mineral and 
herbal supplements
Placebo
16 weeks CRT, IDRM, SI, SWM, and CM, 
blood biomarkers relevant to 
cognition
In cognitively healthy older people, 
multivitamin supplementation 
improved a number of cognitive-
related blood biomarkers, but 
these biomarker changes were 
not accompanied by no significant 
improvement in cognitive functions
Strike et 
al., 2016 21
27 postmenopausal women
Aged: 60-84 years
Nutraceutical formulation 
providing: DHA (1 g/day), 
EPA (160 mg/day), Ginkgo 
biloba, phosphatidylserine, 
α-tocopherol, folic acid, 
and vitamin B12
Placebo
6 months MOT, VRM, and PAL, mobility 
was assessed by VICON 9 
motion capture camera system 
synchronized with Kistler force 
plates; blood fatty acid levels 
by pin-prick analysis
In this RCT, multinutrient 
supplementation improved cognition 
and mobility in healthy older females 
suggesting a potential role in
reducing the decline to frailty
Van de Rest et 
al., 2014 22
127 frail or pre-frail older
subjects
Mean age: 79 years
Protein (30g/day)
Protein + physical exercise
Placebo
Placebo + physical 
exercise
24 weeks MMSE, TMT-A and -B, WLT, 
SCWT, FBDS-WAIS, VFT, and 
reaction time tasks
3 day dietary record
Significant improvement of 
information processing speed in the 
protein plus physical exercise group
Ngandu et al., 
2015 23
1260 nondemented older
subjects
Aged: 60-77 years
Multidomain lifestyle 
intervention
Control group
2 years A comprehensive NTB Z score Findings from this long-term, RCT 
suggested that a multidomain 
intervention could improve or 
maintain cognitive functioning in at-
risk older people
MeDi: Mediterranean diet; EVOO: extravirgin olive oil; MMSE: Mini-Mental State Examination; AVLT: Rey Auditory Verbal Learning Test; ASF: Animals Semantic Fluency; DS-WAIS: Digit Span 
subtest from the Wechsler Adult Intelligence Scale; VPA-WAIS: Verbal Paired Associates from the Wechsler Memory Scale; CTT: Color Trail Test; 3MSE: modified Mini-Mental State Examination; 
RAND36: RAND 36-Item Health Survey; WHI: Women’s Health Initiative; FFQ: food frequency questionnaires; IPT: Identical Pictures Test; NC: Number Comparison task; TMT-A: Trail Making Test - A; 
TMT-B: Trail Making Test -B; FBDS-WAIS: Forward and Backward Digit Span task; CF: Category Fluency; COWAT: Controlled Oral Word Association Test; DST: Digit Symbol Tests; SCWT: Stroop 
Color-Word Test; DS-WAIS-III: Digit Symbol subtest from the Wechsler Adult Intelligence Scale- III; HVLT-R: the Hopkins Verbal Learning Test-Revised; CRT: Choice Reaction Time; IDRM: Immediate 
and Delayed Recognition Memory; SI: Stroop Interference tasks; SWM: Spatial Working Memory; CM: Contextual Memory; MOT: psychomotor response latency; VRM: Verbal Recognition Memo-
ry; PAL: paired associate learning; WLT: Word Learning Test, SCWT: Stroop Color-Word Test, VFT: Verbal Fluency Test; PUFAs: polyunsaturated fatty acids; NTB: neuropsychological test battery
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Table II. Randomized clinical trials evaluating the efficacy of nutritional intervention using a macronutrient approach in preventing 
the onset of late-life cognitive disorders and dementia in cognitively healthy subjects aged over 60 years (2014-2016).
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional assessment
Main Results
Cognitive results
Protein supplementation
Van der 
Zwaluw et al., 
2014 24
65 frail or pre-frail older
subjects
Mean age: 79 years
Proteins (30 g/day)
Placebo
24 weeks MMSE, TMT-A and -B, WLT, 
SCWT, FBDS-WAIS, VFT, and 
reaction time tasks
3 day dietary record
Protein supplementation improved 
reaction time performance in pre-frail 
and frail older adults, but
did not improve other cognitive 
functions
Szcześniak et 
al., 2014 25
51 older subjects
MMSE ± 15
Mean age: 81 ± 7 years in 
CRC group and 80.5 ± 7.5 
years in placebo group
CME containing 40% 
of CRC (2:1 ratio of 
anserine to carnosine) was 
administered 2.5 g/day
Placebo
13 weeks MMSE, STMS, and CDR A significant improvement was found 
after supplementation in specific 
subscores of STMS, a test evaluating 
global cognitive functions, such as 
construction/copying, abstraction, and 
recall 
Rokicki et al., 
2015 26
31 cognitively healthy 
participants
Aged: 42-78 years
Twice- daily doses of the 
imidazole dipeptide formula 
(500 mg)
Placebo
3 months ADAS cog, WMS LM 1 and 2, 
and BDI
Functional MRI
In the CRC group, better verbal 
episodic memory performance and 
decreased connectivity on functional 
MRI were found
Hisatsune et 
al., 2016 27
39 cognitively healthy 
participants
Mean age: 69.2 years
Twice-daily doses of the 
imidazole dipeptide formula 
(500 mg)
Placebo
3 months ADAS cog, WMS LM 1 and 2, 
BDI, SF-36, MMSE
Serum concentrations of 27 
cytokines
Perfusion MRI
CRC supplementation showed a 
significant beneficial effect on verbal 
episodic memory and brain perfusion 
in older adults
Fatty acid supplementation
Witte et al., 
2014 28
65 cognitively healthy older 
subjects
MMSE ± 26
Mean Age: 63.9 ± 6.6 
years
n-3 PUFA group received 
fish oil capsules with 2.2 g 
of n-3 PUFAs (1320 mg EPA 
+ 880 mg DHA, given as 
1000 mg fish oil and 15 mg 
vitamin E)
Placebo (sunflower oil)
26 weeks VF, TMT-A and -B, SCWT, AVLT, 
FBDS-WAIS, STAI 1 and 2
Erythrocyte membrane fatty 
acid composition
MRI
Supplementation with high levels of 
n-3-PUFAs demonstrated enhanced 
executive
functions in healthy older adults after 
26 weeks and improved white matter 
microstructural integrity, regional 
gray matter volume, and vascular 
parameters
Jaremka et 
al., 2014 29
138 cognitively healthy 
older subjects
Mean age: 51.0±7.8 years
1.25 g/day of n-3 PUFAs
2.50 g/day of n-3 PUFAs
Placebo
The fish oil supplements 
contained a 7:1 ratio of EPA 
to DHA
4 months 20-item UCLA loneliness scale, 
CVLT -II, DS-WMS-III, LNS-
WMS-III, SS- WMS-III, TMT, 
COWAT
Plasma levels of n-6 and n-3 
PUFAs.
Lonelier people within the placebo 
condition had poorer verbal episodic 
memory post-supplementation, as 
measured by immediate and long-
delay free recall, than their less lonely 
counterparts. The plasma n-6 PUFAs: 
n-3 PUFAs ratio data mirrored these 
results
Mahmoudi et 
al., 2014 30
199 older individuals with 
normal or mild to moderate 
cognition impairment
Aged ≥ 65 years
180 mg of DHA + 120 mg 
of EPA
Placebo
6 months MMSE, AMT
Plasma cholesterol, CRP, 
fasting blood sugar
No significant effects on cognitive 
outcomes
Chew et 
al., 2015 31
3741 partecipants
Mean Age: 72.7 years
n-3 PUFAs (1 g) and/or 
lutein (10 mg)/zeaxanthin 
(2 mg)
Placebo
All participants were also 
given varying combinations 
of vitamins C, E, beta 
carotene, and zinc
5 years HHI, CES-D, TICS-M, TICS-M 
Recall, AC, LF, AF, LM-WMS-
III-1 & 2, DB, and DR-WMS-
III-RP
No significant effects on cognitive 
outcomes
u
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after supplementation was found in specific subscores of 
a test evaluating global cognitive functions, such as con-
struction/copying, abstraction, and recall (Tab. II) 25. After 
3 months of imidazole dipeptide formula supplementation 
containing 500 mg of CRC supplementation (carnosine 
and anserine, ratio 1/3) to 31 healthy participants, the 
CRC group had not only a better verbal episodic memo-
ry performance but also, at functional MRI, a decreased 
connectivity in the default mode network, the posterior 
cingulate cortex and the right fronto-parietal network, as 
compared with the placebo group. Furthermore, there 
was a correlation between the extents of cognitive and 
neuroimaging changes suggesting that daily CRC sup-
plementation could impact cognitive function and that 
network connectivity changes may be associated with 
its effects (Tab.  II)  26. These findings were confirmed in 
another RCT including 39 healthy older adults assigned 
to a CRC supplementation (carnosine and anserine) or 
placebo for three months. CRC group showed signifi-
cant preservation in delayed recall verbal memory com-
pared to the placebo group, but not in the immediate 
recall test, suggesting that CRC supplementation may 
have a beneficial effect on verbal memory registration, 
but not on short-term working verbal memory. Blood 
analysis revealed a decreased secretion of inflammatory 
cytokines in the CRC group, including CCL-2 (MCP-1) 
and interleukin (IL)-8. Furthermore, perfusion MRI analy-
sis using arterial spin labeling showed a suppression of 
the age-related decline in brain blood flow in the posteri-
or cingulate cortex area in the CRC group compared to 
the placebo group suggesting a protective role of CRC 
supplementation on brain perfusion (Tab. II) 27. 
fatty aciDs
In AD brains, it has been reported the lack of enzyme 
responsible for converting choline into acetylcholine, 
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional assessment
Main Results
Cognitive results
Fatty acid supplementation
Pase et al., 
2015 32
160 cognitively healthy 
older volunteers
Aged: 50-70 years
Multivitamin combined with 
ﬁsh oil (3 g)
Multivitamin combined with 
ﬁsh oil (6 g)
Placebo multivitamin 
combined with ﬁsh oil (6 g)
Placebo multivitamin 
combined with placebo ﬁsh 
oil (Sunola oil)
16 weeks SUCCAB measuring
reaction time, cognitive 
processing speed, short-term 
memory, and visual memory
BP variables
Absolute
increases in the red blood cell 
n-3/n-6 ratio were associated with 
improvements in spatial working 
memory. The 6 g fish oil without 
the multivitamin group displayed a 
significant decrease in aortic pulse
pressure and aortic augmentation 
pressure, two measures of aortic BP 
and aortic stiffness
Tokuda et al., 
2015 33
113 older nondemented 
Japanese men
Mean age: 59.6 years
LC-PUFA-containing oil 
(including ARA 120 mg/die, 
DHA 300 mg/die and EPA 
100 mg/die)
Purified olive oil
4 weeks Event-related potential P300 
and POMS
LC PUFA plasma analysis
Diet history questionnaire, 
semi-quantitative FFQ, and 
study diary
Changes in P300 latency were 
significantly different between the 
placebo group and the LC PUFA group 
after supplementation
Külzow et al., 
2016 34
44 cognitively healthy 
individuals
Mean age: 62 ± 6 years
n-3 PUFAs (2.2 g/day)
Placebo
26 weeks LOCATO assessing OLM in 
older adults, AVLT, and PANAS
Erythrocyte membrane fatty 
acid composition, serum 
biomarkers and APOE 
genotyping
Dietary habit questionnaire
Performance in cued recall in a 
OLM task was sensitive in detecting 
beneficial effects of n-3 PUFA 
supplementation. Omega-3-index 
significantly increased in the n-3 PUFA 
group and decreased in the placebo 
group
MMSE: Mini-Mental State Examination; TMT-A: Trail Making Test - A; TMT-B: Trail Making Test -B; WLT: Word Learning Test; SCWT: Stroop Color-Word Test; FBDS-WAIS: Forward and Backward 
Digit Span task from the Wechsler Adult Intelligence Scale; VFT: Verbal Fluency Test; CRC: carnosine related compounds; CME: chicken meat extract; STMS: Short Test of Mental Status; CDR: 
Clinical Dementia Rating; ADAS-cog: Alzheimer’s Disease Assessment Scale-Cognition; LM-1 & 2-WMS-: Logical Memory 1 & 2 from Wechsler Memory Scale; BDI: Beck Depression Inventory; 
MRI: magnetic resonance imaging; SF-36: Medical Outcomes Study, 36-item Short Form; MCS: Mental Health Component Summary score; PCS: Physical Health Component Summary; n-3 PUFA: 
n-3 polyunsaturated fatty acids; VF: Verbal Fluency; AVLT: Auditory Verbal Learning Test; STAI 1 and 2: Spielberger’s State-Trait Angst Inventar; EPA: eicosapentaenoic acid; DHA: docosahexaenoic 
acid; CVLT: California Verbal Learning Test, Second Edition; DS-WMS-III: Digit Span subtest from the Wechsler Memory Scale – Third Edition; LNS-WMS-III: Letter-Number Sequencing subtest 
from the Wechsler Memory Scale – Third Edition; SS-WMS-III: Spatial Span subtest from the Wechsler Memory Scale – Third Edition; COWAT: Controlled Oral Word Association Test; AMT: Ab-
breviated Mental Test score; CRP: C-reactive protein; CES-D: Center for Epidemiologic Studies’ Depression Scale; TICS-M: Telephone Interview Cognitive Status-Modified; AC: Animal Category; 
LF: Letter Fluency; AF: Alternating Fluency; LM-WMS-III-1 & 2: Logical Memory 1 & 2 from Wechsler Memory Scale – Third Edition; DB: Digits Backward; DR-WMS-III-RP: Delayed Recall from 
Wechsler Memory Scale – Third Edition Recall Paragraph; SUCCAB: Swinburne University Computerised Cognitive Assessment Battery; BP: blood pressure; LC PUFA: long-chain polyunsaturated 
fatty acids; ARA: arachidonic acid; POMS: Profile of Mood Status; FFQ: food frequency questionnaires; OLM: object-location memory; PANAS: Positive and Negative Affect Schedule; APOE; 
apolipoprotein E
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therefore, the first dietary lipids proposed as potential 
therapeutic agents in AD were lecithin, the major dietary 
source of choline, and alpha-lipoic acid, both able to 
increase acetylcholine production  47. However, results 
from clinical trials were contrasting and further RCTs 
are required to evaluate their role as therapeutic sup-
plements in order to delay cognitive impairment. Many 
epidemiological studies have demonstrated that dietary 
fatty acids may play a key role in several pathological 
conditions. Long-chain (LC) PUFAs, such as DHA, 
EPA, and arachidonic acid (ARA) are among the most 
studied macronutrients in late-life cognitive disorders 
and neurodegeneration  48. In particular, an increasing 
body of epidemiological evidence suggested that ele-
vated saturated fatty acids (SFAs) could have negative 
effects on MCI, while a clear reduction of risk for cogni-
tive decline has been found in population samples with 
elevated fish consumption, high intake of monounsa-
turated fatty acids (MUFAs) and LC PUFAs, particularly 
n-3 PUFAs 49. Despite the strong evidence in cognitive 
decline prevention coming from observational studies, 
findings coming from RCTs were controversial conside-
ring the great heterogeneity of samples and outcome 
measures as well as neuropsychological tools or MRI 
findings (Tab.  II)  28-34. Interesting data have been sug-
gested from one RCT on 65 healthy subjects showing 
not only a significant increase in executive functions 
and letter fluency in the n-3-PUFA group compared 
with placebo, but also neuroimaging modifications after 
supplementation suggesting a pathobiological effect of 
n-3 PUFAs (Tab. II) 28. In fact, n-3 PUFA supplementa-
tion led to significant beneficial effects on white matter 
microstructural integrity and significant increases in 
regional gray matter volume compared with placebo 
in specific regions as left hippocampus, precuneus, 
superior temporal, inferior parietal and postcentral gyri, 
and in the right middle temporal gyrus and beneficial 
effects on carotid intima media thickness and diastolic 
blood pressure. Improvements in executive functions 
correlated positively with changes in omega-3-index 
and peripheral brain-derived neurotrophic factor, and 
negatively with changes in peripheral fasting insulin 
(Tab. II) 28. In another RCT, n-3 PUFA supplementation 
was effective on immediate and long-delayed free re-
call only in healthy lonelier participants. In fact, lonelier 
people within the placebo condition had poorer verbal 
episodic memory post-supplementation, as measured 
by immediate and long-delay free recall, than their less 
lonely counterparts. This effect was not observed in the 
n-3 PUFA 1.25 g/day and n-3 PUFA 2.5 g/day supple-
mentation groups. The plasma n-6 PUFAs: n-3 PUFAs 
ratio data mirrored these findings (Tab. II) 29. However, 
findings from two RCTs showed that oral supplemen-
tation with n-3 PUFAs had no statistically significant 
effect on cognitive functions (Tab. II) 30 31. In particular, 
in a RCT on 199 older subjects with normal or mild to 
moderate cognition impairment, low dose n-3 PUFAs 
(180 mg of DHA + 120 mg of EPA) for 6 months had no 
significant beneficial effects on improvement of cogni-
tion or prevention of cognitive decline in older people. 
However, considering only the cognitively healthy sub-
jects, authors noticed near significant less decrement in 
global cognitive scores in n-3 PUFA group compared 
to placebo (Tab. II) 30. Moreover, in a large RCT includ-
ing 3741 older participants, randomized to receive n-3 
PUFAs (1 g) and/or lutein (10 mg)/zeaxanthin (2 mg) vs 
placebo for 5 years no statistically significant differenc-
es in change of cognitive scores between groups were 
reported (Tab. II) 31. Furthermore, several RCTs reported 
promising findings only in specific cognitive domains 
evaluated with several neuropsychological tests. In fact, 
in a RCT including 160 healthy participants randomized 
to multivitamins with fish oil for 16 weeks, the red blood 
cell n-3/n-6 ratio increases were associated with im-
provements in spatial working memory (Tab. II) 32. Some 
trials reported promising results in specific cognitive 
domains with higher doses of LC PUFAs compared to 
general dietary intake levels. Interestingly, a RCT sug-
gested a potential role in improving cognitive function 
of LC PUFAs also at low doses of supplementation 
similar to general dietary intake. In fact, in 113  non-
demented older Japanese participants, after 4 weeks 
of supplementation with LC PUFA-containing oil (DHA 
300 mg/day, EPA 100 mg/day, and ARA 120 mg/day) 
or purified olive oil as placebo, changes in P300 laten-
cy, a measure of cognitive processes, were significantly 
different between the placebo group and the LC PUFA 
group. Significant increases in DHA and ARA contents 
in plasma phospholipids were observed in the LC PUFA 
group, while no changes were observed in the placebo 
group (Tab. II) 33. In another RCT conducted on 44 cog-
nitively healthy individuals, the recall of object locations 
was significantly better after n-3 PUFA supplementa-
tion (daily dose of 1.320 mg EPA + 880 mg DHA for 
26  weeks) compared with placebo. No significant 
correlation between changes in memory performance 
and omega-3-index were observed, suggesting that 
memory benefits were not associated in a simple linear 
fashion with changes in omega-3-index (Tab. II) 34. 
NUTRITIONAL INTERVENTION THROUGH 
MICRONUTRIENT CHANGES
non-flavonoiD polyphenols
Table  III shows selected RCTs published in the last 
three years (2014-2016) that evaluated the efficacy of 
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nutritional intervention through supplementation of di-
etary micronutrients in preventing the onset of late-life 
cognitive disorders and dementia in cognitively healthy 
subjects aged over 60 years  35-43. Several classes of 
polyphenols have been investigated for their potential 
anti-ageing and neuroprotective properties, including 
flavonoids, commonly found in berries, grapes and red 
wine, and non-flavonoids, i.e., curcumin from turmeric 
and resveratrol from grapes and red wine 50. An increas-
ing body of evidence suggested that consumption of 
polyphenols such as resveratrol and flavonoids may 
have potential beneficial effects on cognition, particu-
larly on declarative and spatial memory, mainly in cogni-
tively healthy individuals 50. However, results from RCTs 
were contrasting considering also the methodological 
inconsistencies of studies. On the other hand, findings 
from observational studies suggested that moderate 
consumption of red wine, rich in specific polyphenolic 
compounds such as quercetin, myricetin, catechins, 
tannins, anthocyanidins, resveratrol, and ferulic acid, 
has been associated with a lower incidence of cognitive 
decline, suggesting a protective role against demen-
tia  51. These data were confirmed from a recent RCT 
(Tab. III) 35. In fact, a trial including 46 cognitively healthy 
older adults randomly assigned to receive a daily intake 
of 200 mg of resveratrol and 320 mg of quercetin or 
placebo showed that supplementary resveratrol over a 
period of 26 weeks improved retention of words over 
a 30 min delay and functional connectivity of the hip-
pocampus with frontal, parietal, and occipital areas in 
healthy older overweight adults compared with placebo 
(Tab. III) 35. Among non-flavonoid polyphenols, curcum-
in has been extensively reported to demonstrate many 
beneficial biological effects including anti-cancer, anti-
oxidant and anti-inflammatory activities 52.
For the prevention of cognitive-related outcomes in older 
age, promising results were reported in a one-year RCT 
in 96 cognitively normal subjects randomized to receive 
placebo or 1500 mg/d of bioenhanced preparation of 
curcumin (BCM-95®CG). A significant time×treatment 
group interaction was observed for global cognitive 
function, explained by a function decline in the placebo 
group at 6 months that was not found in the interven-
tion group (Tab. III) 36.
flavonoiDs
Flavonoids [flavanols (catechin, epicatechin, epigal-
locathechin, and epigallocatechingallate-EGCG), fla-
vonols (quercetin and kaempferol), flavones (luteolin 
and apigenin), isoflavones (daidzein and genistein), 
flavanones (esperetin and naringenin), and anthocyan-
idins (pelargonidin, cyanidine, and malvidin) have also 
been proposed to prevent or treat cognitive impairment 
or dementia  45  53. Recent RCTs showed significant 
improvements in some cognitive domains after flavo-
noid interventions 54. However, the great heterogeneity 
in sample, flavonoid dose, follow-up and cognitive tests 
used led to inconsistent findings 54. In a very interesting 
RCT on 37 healthy older adults who consumed a high 
cocoa flavanol-containing diet (900 mg cocoa flavanols 
and 138 mg of epicatechin) or a low-dose one (10 mg 
cocoa flavanols and < 2 mg epicatechin) with or with-
out aerobic exercise for 12  weeks, the high-flavanol 
intervention was found to enhance dentate gyrus (DG) 
function measured by functional MRI and by cognitive 
testing, suggesting the crucial role of DG dysfunc-
tion in age-related cognitive decline and the potential 
beneficial effects of flavonoid supplementation on DG 
function (Tab. III) 37. On the contrary, in a trial including 
300  cognitively healthy postmenopausal women ran-
domized to receive 25 grams of isoflavone-rich soy pro-
tein for 2.7 years, long-term changes in isoflavonoids 
were not associated with global cognition and episodic 
memory, although greater isoflavonoid exposure was 
associated with decrements in general intelligence 
(Tab. III) 38. Promising results come from other two trials 
with a 8 week follow-up (Tab.  III)  39 40. In particular, in 
a RCT including 37 healthy participants randomized to 
receive two different flavanone-rich supplementations, 
high flavanone and low flavanone orange juice drinks, 
global performance, executive function, and episodic 
memory, and immediate recall were significantly better 
after the high flavanone drink than the low flavanone 
drink (Tab. III) 39. Similar positive findings were found in 
the second RCT for a drink containing a high dose of 
cocoa flavanols (993 mg/day) compared to a low dose 
drink (993 mg/day) in cognitively healthy participants for 
specific cognitive domains (i.e., executive function and 
verbal fluency) suggesting a possible protective role in 
age-related cognitive dysfunction, possibly through an 
improvement in insulin sensitivity (Tab. III) 40. 
hoMocysteine-relateD vitaMins
A possible modifiable risk factor of dementia is an 
elevated plasma Hcy level. In fact, Hcy may be tox-
ic for neurons and vascular endothelial cells  55, and 
cross-sectional and prospective studies have shown 
associations between elevated Hcy levels and cognitive 
decline and dementia 56. Hcy levels can be lowered by 
supplementation with folic acid (vitamin B9) and vitamin 
B12  57. Although observational studies have shown a 
strong association between poor vitamin B6, B12, and 
folate levels and increased risk of dementia, suggesting 
a preventive and protective role of these micronutrients, 
evidence from RCTs appeared to be unclear (Tab. III) 41-
43. In fact, in two RCTs, no significant effect of supple-
mentation of Hcy-related vitamins on cognitive function 
were found (Tab.  III)  41 42. In particular, in a large RCT 
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Table III. Randomized clinical trials evaluating the efficacy of nutritional intervention using a micronutrient approach in preventing 
the onset of late-life cognitive disorders and dementia in cognitively healthy subjects aged over 60 years (2014-2016).
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional assessment
Main results
Non-flavonoid polyphenols
Witte et 
al., 2014 35
46 cognitively healthy 
overweight older 
individuals
Aged: 50-75 years
Daily intake of four 
capsules (in total 200 mg 
of resveratrol and 320 mg 
of quercetin)
Placebo
All subjects received a 13
week supply of capsules 
and another 13 week 
supply after 3 months
26 weeks AVLT
Functional MRI and DTI MRI
Lipid metabolism, 
inflammation, neurotrophic 
factors, and vascular 
parameters
Significant positive effect of 
resveratrol on retention of words 
over 30 minutes and functional 
connectivity of the hippocampus 
with frontal, parietal, and occipital 
areas in healthy older overweight 
adults compared with placebo 
Rainey-Smith et 
al., 2016 36
96 community-dwelling 
older adults without 
significant cognitive 
impairments
Mean age: 66 ± 6.6 years
1500 mg/day of 
bioenhanced preparation of 
curcumin (BCM-95®CG)
Placebo
12 months CCRT, DASS, SF-36,
PRMQ-16, MoCA; AVLT, COWAT, 
WDSS-WAIS-R, and the 
computerized CogState battery
APOE genotyping
A significant time×treatment group 
interaction for global cognition, 
explained by a function decline in 
the placebo group at 6 months that 
was not found in the intervention 
group. No differences for all other 
clinical and cognitive measures
Flavonoids
Brickman et 
al., 2014 37
37 cognitively healthy, 
sedentary older subjects
Aged: 50-69 years
High flavanol intake + 
aerobic exercise
High flavanol intake
Low flavanol intake + 
aerobic exercise
Low flavanol intake
12 weeks ModBent task, AVLT
Functional MRI
High dietary flavanol consumption 
enhanced dentate gyrus function 
in the aging human hippocampal 
circuit, independently of exercise
St John et 
al., 2014 38
300 cognitively healthy 
women
Mean age: 61 years
25 g of isoflavone-rich soy 
protein (91 mg of aglycone 
weight isoflavones: 52 mg 
genistein, 36 mg daidzein, 
and 3 mg glycitein)
Milk protein-matched 
placebo provided daily
2.7 years WTAR, CES-D; 
neuropsychological test battery 
evaluating general intelligence 
(executive/expressive/
visuospatial tasks), verbal 
episodic memory (list learning/
logical memory), and visual 
episodic memory
Overnight urine excretion 
of isoflavonoids and fasting 
plasma levels of isoflavonoids
Long-term changes in isoflavonoids 
were not associated with global 
cognition. Increasing isoflavonoid 
exposure from dietary supplements 
was, however, associated with 
decrements in general intelligence 
but not memory
Kean et al. 
2015 39
37 cognitively healthy older 
subjects
Mean age: 66.7 years
High flavanone drink 
(305 mg/day)
Low flavanone drink 
(37 mg/day)
8 weeks CERAD immediate and delayed 
verbal recalls and serial 
sevens, SWM, DSST-WAIS, 
VPA-WMS-III, LM, LF, and Go-
NoGo
Daily consumption of high dose 
flavanone-rich orange juice was 
associated with benefits for global 
cognitive function, executive function, 
and episodic memory, mainly 
immediate recall
Mastroiacovo 
D et al. 2015 40
90 cognitively healthy older 
subjects
Mean age: 69.5 years
993 mg flavanols/day
520 mg flavanols/day
48 mg flavanols/day
8 weeks MMSE, TMT-A and -B, and VFT High dose flavanol consumption 
caused significant effects on 
executive function and verbal 
fluency
Van der Zwaluw 
et al., 2014 41
2.919 older participants 
with Hcy levels between 12 
and 50 µmol/L
Mean age: 74.1 + 6.5 years
Daily either a tablet with 
400 µg folic acid and 
500 µg vitamin B12
Placebo
Both tablets contained 
15 µg vitamin D3
2 years MMSE, AVLT, FBDS-WAIS, 
TMT-A and –B, SCWT, SDMT, 
and LF
Blood biomarkers
This large RCT did not reveal 
beneficial effects of supplementation 
with vitamin B12 and folic acid on 
the cognitive domains of episodic 
memory, attention and working 
memory, information processing 
speed, and executive function
u
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on 2.919 older participants with elevated Hcy levels, 
a 2-year folic acid and vitamin  B12 supplementation 
did not significantly improve cognitive performance in 
all four cognitive domains investigated (episodic mem-
ory, attention and working memory, information pro-
cessing speed, and executive function). Interestingly 
it was reported a small difference in global cognition, 
that the authors concluded as attributable to chance 
(Tab. III) 41. The other RCT included 201 healthy cogni-
tive older adults with moderate vitamin B12 deficiency. 
In this one-year follow-up trial, there was no effect of 
B12 supplementation peripheral nerve or central mo-
tor function outcome or cognitive function (Tab.  III)  42. 
However, another RCT suggested more promising find-
ings with a supplementation containing 800 µg/day of 
folate, 10 mg of vitamin B6 and 25 µg of vitamin B12 
in 104 older patients with hyperhomocysteinemia. This 
supplemtation improved cognitive function in terms 
of global cognitive scores and four subtests (mental 
speed, visuo-spatial ability, working memory, and visual 
memory) (Tab. III) 43.
CONCLUSIONS AND FUTURE DIRECTIONS
In the last decade, while the association between diet 
and cognitive function or dementia has been largely 
investigated in observational studies, there was a lack 
of evidence from RCTs dealing with the prevention of 
late-life cognitive disorders though dietary interven-
tion in older adults without cognitive dysfunction. In 
the present article, we reviewed RCTs published in 
the last three years (2014-2016) exploring nutritional 
intervention efficacy in preventing the onset of late-life 
cognitive disorders and dementia in cognitively healthy 
subjects aged over 60 years and using different levels 
of investigation (i.e., dietary pattern changes/medi-
cal food/nutraceutical supplementation/multidomain 
approach and dietary macro- and micronutrient ap-
proaches). From the reviewed RCTs, there was mod-
erate evidence that nutritional intervention through 
dietary pattern changes, medical food/nutraceutical 
supplementation, and multidomain approach im-
proved specific cognitive domains or cognitive-related 
blood biomarkers. Furthermore, there was convincing 
evidence that protein supplementation improved spe-
cific cognitive domains. For fatty acid supplementa-
tion, mainly LC PUFAs, there was emerging evidence 
suggesting an impact of this approach in improving 
specific cognitive domains, MRI findings, and/or cog-
nitive-related biomarkers also in selected subgroups 
of older subjects although some results were conflict-
ing. Among selected RCTs that evaluated the efficacy 
of nutritional intervention through supplementation 
of dietary micronutrients, there was evidence of an 
impact of non-flavonoid polyphenol and flavonoid 
supplementations in improving specific cognitive 
domains and/or MRI findings. Finally, there was only 
low evidence suggesting efficacy of intervention with 
homocysteine-related vitamins in improving cognitive 
functions, dementia incidence, or cognitive-related 
biomarkers in cognitively healthy older subjects.
Reference Study sample Intervention(s) Duration Cognitive-related 
outcomes and 
nutritional assessment
Main results
Homocysteine-related and antioxidant vitamins
Dangour et al., 
2015 42
201 older subjects 
with moderate 
vitamin B-12 deficiency 
(serum vitamin B-12 
concentrations: 107-
210 pmol/L) in the absence 
of anemia
Mean age: 80 years
1 mg crystalline 
vitamin B-12
Placebo
12 months CVLT, SLMT, simple and choice 
reaction time, and VFT
Peripheral motor and sensory 
nerve conduction and central 
motor conduction assessment
No evidence of an effect on 
peripheral nerve or central motor 
function outcome or on cognitive 
function 
Cheng et al., 
2016 43
104 older participants with 
hyperhomocysteinemia
Mean age: 71.7 ± 8.8 years
Vitamin B group, which 
received 800 µg/day of 
folate, with 10 mg of 
vitamin B6 and 25 µg of 
vitamin B12
Placebo
14 weeks BCATs
Serum measure of tHcy, 
vitamin B6, vitamin B12, and 
folate
Improvement with vitamin B 
supplementation in global cognitive 
scores and four subtests (mental 
speed, visuo-spatial ability, working 
memory, and visual memory)
AVLT: Auditory Verbal Learning Test; DTI: diffusion tensor imaging; MRI: magnetic resonance imaging; CCRT: Cambridge Contextual Reading Test; DASS; Depression Anxiety Stress Scales; 
PRMQ-16: 16 item self-report Prospective and Retrospective Memory Questionnaire; MoCA: Montreal Cognitive Assessment; WDSS-WAIS-R: Wechsler Digit Symbol Scale from Wechsler Adult 
Intelligence Scale revised; APOE; apolipoprotein E; Mod Bent; modified Benton Visual Retention Test; WTAR: Wechsler Test of Adult Reading; CERAD: Consortium to Establish a Registry for Alzhei-
mer’s Disease; SWM: Spatial Working Memory; DSST-WAIS: Digit Symbol Substitution Test from the Wechsler Adult Intelligence Scale; VPA-WMS-III: Verbal Paired Associates from the Wechsler 
Memory Scale– Third Edition; LM: Letter Memory; LF: Letter Fluency; TMT-A: Trail Making Test - A; TMT-B: Trail Making Test -B; VFT: Verbal Fluency Test; Hcy: homocysteine; FBDS-WAIS: Forward 
and Backward Digit Span task from the Wechsler Adult Intelligence Scale; SCWT: Stroop Color-Word Test; SDMT: Symbol Digit Modalities Test; CVLT: California Verbal Learning Test, Second 
Edition; SLMT: symbol letter modality test; BCATs: Basic Cognitive Aptitude Tests
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In the last five years, several meta-analyses and sys-
tematic/scoping reviews investigated the efficacy of 
different nutritional supplementations in preventing 
late-life cognitive disorders in cognitively healthy older 
adults 4-7. However, these meta-analyses and system-
atic/scoping reviews investigated also observational 
studies and not only RCTs  4  7, included also younger 
subjects 5, and were limited to specific macronutrients 
(i.e., n-3 PUFAs) 4-7, micronutrients 5 6, or dietary pattern 
changes/nutraceuticals 4 7. In particular, some of these 
studies found that n-3 PUFAs were associated with 
better global cognition and some specific cognitive do-
mains 4 6 7. B vitamins, and vitamin E supplementations 
did not affect cognition 5 or had limited efficacy 6 7, while 
adherence to the MeDi was significantly associated 
with better cognitive performance and less cognitive 
decline 4.
The absence of disease-modifying treatment for AD 
patients leads to the investigation of a multimodal 
alternative therapeutic or preventive approaches by 
targeting modifiable risk factors. Therefore, in the last 
years, a growing interest has concerned the relation 
between nutrients and cognitive impairment in the 
earlier phases, considering the multifactorial effects of 
nutrition in human diseases. In fact, it is well known that 
dietary habits may influence several cardiometabolic 
risk factors, as visceral adiposity, blood pressure, glu-
cose-insulin metabolism, lipids levels, but also hepatic 
function, endothelial health, microbiome function, and 
several biological processes as oxidative stress, inflam-
mation, both involved in human aging. Despite several 
promising findings coming from observational studies 3, 
evidence suggesting a potential preventive effective-
ness of nutritional intervention in healthy olders to delay 
the onset of cognitive decline are still scarce and quite 
contrasting. Considering that is unlikely that a single 
nutrient could significantly improve cognition and delay 
cognitive impairment, several observational studies and 
RCTs proposed combination of micro/macronutrients 
or medical foods/nutraceuticals as potential preven-
tive approaches in olders with promising results  3 4 6 7 
Furthermore, a multidimensional approach consisting 
in healthy life style (healthy dietary habits in combina-
tion with physical activity) seems the best intervention 
in olders. In fact it is well known that there is a strong 
bidirectional interaction between cognitive performance 
and other main outcomes in olders that have to be con-
sidered as physical and cognitive frailty and disability 58.
However, some limitations should be reported for the 
present systematic review article. An important limita-
tion was linked to the great heterogeneity of included 
RCTs not only in terms of study samples and trial dura-
tions, but also in relation to the outcome measures and 
nutrients intake quantification. This heterogeneity made 
really difficult to give clear answers about the efficacy 
of dietary intervention in older adults without cognitive 
dysfunction. However, there are several interesting con-
cepts coming from the reviewed RCTs to underline. The 
first one was the emerging use of innovative measures 
of dietary habits, not only daily questionnaire but also 
biomarkers dosage as blood exams or urinary excre-
tion. This resulted into an objective quantification of 
nutrient supplementation but also of nutritional status 
of patients at baseline. Furthermore, as shown in the 
present systematic review, recent RCTs underlined the 
importance to consider emerging cognitive-related 
outcomes in order to achieve more significant and ob-
jective results. Therefore, in addition to clinical scales 
and cognitive tests, serum and cerebrospinal fluid 
(CSF) biomarkers, neuroimaging and other cognitive-
related biomarkers have been proposed. As a result, 
these findings could give us the possibility to better 
understand and quantify the nutrition-related impact on 
cognitive impairment and AD pathobiology. In conclu-
sion, dietary pattern change/multidomain approaches, 
macronutrient (i.e., proteins and LC PUFAs) and micro-
nutrient (i.e., non-flavonoid polyphenols and flavonoids) 
supplementations could be really effective in achieving 
cognitive-related outcomes in healthy older subjects 
without cognitive dysfunction. However, to obtain more 
statistically significant and reliable results, RCTs would 
be conducted in larger selected samples characterized 
by well defined cognitive function status, nutritional and 
dietary habits at baseline, with longer follow-up, and 
would include further objective measures of cognitive-
related outcomes as blood or CSF biomarkers and 
neuroimaging findings. 
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